GlaxoSmithKline (LON:GSK)‘s stock had its “hold” rating restated by equities researchers at Shore Capital in a research note issued on Thursday.

Several other equities research analysts also recently issued reports on the company. J P Morgan Chase & Co reissued a “neutral” rating and issued a GBX 1,330 ($17.81) price objective on shares of GlaxoSmithKline in a research note on Thursday. UBS raised GlaxoSmithKline to a “buy” rating and set a GBX 1,550 ($20.76) price objective for the company in a research note on Monday. HSBC reissued a “buy” rating and issued a GBX 1,925 ($25.78) price objective on shares of GlaxoSmithKline in a research note on Wednesday, November 22nd. Jefferies Group reduced their price objective on GlaxoSmithKline from GBX 1,540 ($20.62) to GBX 1,450 ($19.42) and set a “buy” rating for the company in a research note on Thursday, November 16th. Finally, Investec downgraded GlaxoSmithKline to a “hold” rating and cut their price target for the stock from GBX 1,800 ($24.11) to GBX 1,390 ($18.62) in a research note on Monday, November 6th. Three investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of GBX 1,584.29 ($21.22).

Shares of GlaxoSmithKline (LON:GSK) traded down GBX 28 ($0.37) during trading on Thursday, reaching GBX 1,279.50 ($17.14). The company had a trading volume of 16,252,826 shares, compared to its average volume of 11,220,000. GlaxoSmithKline has a 1 year low of GBX 1,291.50 ($17.30) and a 1 year high of GBX 1,724.50 ($23.09).

GlaxoSmithKline (LON:GSK) last announced its quarterly earnings data on Wednesday, October 25th. The company reported GBX 32.50 ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of GBX 31.80 ($0.43) by GBX 0.70 ($0.01). The firm had revenue of GBX 784.30 billion during the quarter. GlaxoSmithKline had a return on equity of 461.88% and a net margin of 17.79%.

In related news, insider Urs Rohner bought 473 shares of the business’s stock in a transaction that occurred on Wednesday, October 25th. The stock was acquired at an average price of GBX 1,518 ($20.33) per share, for a total transaction of £7,180.14 ($9,615.83). Also, insider Simon Dingemans bought 1,076 shares of the business’s stock in a transaction that occurred on Thursday, October 12th. The shares were bought at an average price of GBX 1,527 ($20.45) per share, with a total value of £16,430.52 ($22,004.18). Insiders have bought a total of 1,576 shares of company stock worth $2,400,376 in the last three months.

TRADEMARK VIOLATION WARNING: “GlaxoSmithKline (GSK) Earns “Hold” Rating from Shore Capital” was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2017/11/30/glaxosmithkline-gsk-earns-hold-rating-from-shore-capital.html.

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.